Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia

Not Applicable

Recruiting

• Conditions: Dry Eye; MGD-Meibomian Gland Dysfunction

• Registration Number: NCT06287879
• Lead Sponsor: Zhongnan Hospital

Brief Summary

Renal anemia refers to anemia in which the absolute or relative production of erythropoietin (EPO) is insufficient due to various kidney diseases, and uremic toxins affect erythropoietin production and its lifespan. Common treatment drugs for renal anemia include erythropoietin EPO and Roxadustat (FG-4592).

Medical history information was collected from patients with renal anemia who visited the ophthalmology department with dry eye symptoms.

This study will help to determine the function and morphological characteristics of meibomian gland in patients with renal anemia

Detailed Description

1. Collect medical records of patients with renal anemia who visited the ophthalmology outpatient department of Zhongnan Hospital and hospitalized patients with renal anemia

2. Patients were divided into Rosallistat group, and EPO group according to their drug use history.

3. The dry eye analysis results of all patients were collected, and the lacrimal river height, tear film rupture time and meibomian gland grade were counted. The results of dry eye examination were analyzed statistically.

4. Complete data collection, conduct statistical analysis, and evaluate the analysis results.

Study Timeline

• Study Start: 2023-04-01
• Status Verified: 2023-11
• Study First Submitted: 2024-02-01
• Study First Submitted QC: 2024-02-27
• Last Update Submitted: 2024-02-27
• Study First Posted: 2024-03-01
• Last Update Posted: 2024-03-01
• Primary Completion: 2024-12-20
• Study Completion: 2024-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• long-term use of Roxadustat or erythropoietin for renal anemia

Exclusion Criteria

• contact lens wearer, history of eye surgeries, systemic health conditions affecting ocular health and those who were unable to cooperate with examinations

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Lacrimal river height	Immediately and six months later	Measured by dry eye analyzer machine
tear break-up time	Immediately and six months later	Measured by dry eye analyzer machine
tear-film lipid layer thickness	Immediately and six months later	Measured by dry eye analyzer machine
meibomian glands two-dimensional digital infrared images	Immediately and six months later	Measured by dry eye analyzer

Trial Locations

Locations (1)

Zhongnan Hospital of Wuhan University; 🇨🇳 Wuhan, Hubei, China